British and Russian scientists are coming together to test a combination of the Oxford-AstraZeneca and Sputnik V vaccines to see if protection against Covid-19 can be improved.
According to researchers, mixing two such vaccines can lead to a better immune response in humans.
The trials, which will take place in Russia, will involve over 18 years, although it is not clear how many people will be involved.
Oxford recently published results showing that their vaccine is safe and effective in human trials.
Researchers are still collecting data on the effectiveness of the vaccine in older age groups while awaiting approval from the UK regulator, MHRA.
AstraZeneca said it was studying combinations of different adenoviral vaccines to see if mixing them would lead to a better immune response and therefore greater protection.
The Oxford vaccine, developed in partnership with AstraZeneca, and the Russian Sputnik vaccine, developed by the Gamaleya Research Institute in Moscow, are similar in that they both contain genetic material from the Sars-CoV-2 protein.
They work differently from the Pfizer-BioNTech vaccine, which is approved in the UK, Canada, Bahrain, Saudi Arabia and recommended for approval by medical experts in the United States.
Joe Biden puts 100 million Covid vaccinations in the first 100 days Pfizer coronavirus vaccine approved in the UK Pfizer vaccine appears to protect 94% of adults over 65
Early results of tests of the Russian vaccine in the last stage showed promising results.
Russia was the first country to register the Covid vaccine for emergency use in August, although it was tested on only a few dozen people.
Sputnik V is now being offered to the Russians as part of a mass vaccination campaign.
AstraZeneca said it was “working with industry partners, governments and research institutions around the world and will soon launch a study with the Gamaleya Research Institute in Russia to see if two adenovirus-based vaccines can be successfully combined.”